Overview

Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod

Status:
Terminated
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This study evaluated disease control during different lengths of treatment transition from natalizumab to fingolimod.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Fingolimod Hydrochloride
Natalizumab